Skip to content

Public FDA record

Z-0355-2023: IMMULITE and IMMULITE 1000 Total Testosterone Assay- In vitro diagnostic use with the IMMULITE and IMMULI

Recall record Z-0355-2023 for Siemens Healthcare Diagnostics, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0355-2023
Company in FDA record
Siemens Healthcare Diagnostics, Inc.
FDA classification date
Dec 2, 2022
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Confirmed an average positive bias of 40% for testosterone concentrations of approximately 660 ng/dL (22.9 nmol/L) and above with the IMMULITE/IMMULITE 1000 Total Testosterone Assay when compared to the IMMULITE 2000/IMMULITE 2000 XPi Total Testosterone Assay. Two (2) lots of Total Testosterone assays for the IMMULITE/IMMULITE 1000, kit lots #515 and #516 were actively distributed to customers when the issue was discovered by Siemens, and they are subject to the correction or removal in this recall (867 total quantity of reagents distributed for each lot). The violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. In both males and female, testosterone results are not used in isolation but are interpreted in conjunction with clinical history and symptomology as well as with other laboratory testing (e.g. gonadotropins and other sex steroids). A delay in the diagnosis may be experienced and medical intervention, such as repeat testing may be required.

Source facts

Action
Siemens has issued an "Urgent Medical Device Correction (UMDC)" IMC 23-02.A.US to US customers via FedEx beginning on 10/25/2022. An Urgent Field Safety Notice (UFSN) IMC 23-02.A.OUS to Outside the US (OUS) customers for distribution and regional reporting to their local competent authorities beginning on 10/25/2022. Letters states reason for recall, health risk and action to take: Please review this letter with your Medical Director. You may continue use of the IMMULITE/IMMULITE 1000 Total Testosterone Assay kit lots listed in Table 1 to report values below 660 ng/dL (22.9 nmol/L) until you receive replacement product in your laboratory. Refer to Figures 1 and 2 for IMMULITE/IMMULITE 1000 Total Testosterone bias information. If you are currently using IMMULITE/IMMULITE 1000 Total Testosterone Assay kit lots listed in Table 1, review your inventory needs of these products, and order replacement products by completing the Field Correction Effectiveness Check Form attached to this letter. Upon acceptance of the re-aligned replacement lots, discontinue use of and discard the products listed in Table 1. Refer to Figures 3 - 6 for expected results with replacement lots. Complete and return the Field Correction Effectiveness Check Form attached to this letter within 30 days. If you have received any complaints of illness or adverse events associated with the products listed in Table 1, immediately contact your local Siemens Healthineers Customer Care Center or your local Siemens Healthineers technical support representative. Please retain this letter with your laboratory records and forward this letter to those who may have received this product. If you have any questions, please contact your Siemens Healthineers Customer Care Center or your local Siemens Healthineers technical support representative.
Initiated
2022-10-25
Root cause
Process control
Distribution
Worldwide Distribution: US (nationwide) to states of: AL, CA, FL, GA, IN, KY, NC, NE, OR, SD, TX, UT; and OUS (Foreign) to countries of: Canada, Mexico, Austria, Argentina, Austria, Bangladesh, Colombia, Brazil, Bulgaria, Costa¿Rica, Cyprus, Estonia, Germany, Greece, India, U.A.E., Italy, Kazakhstan, Latvia, P.R.¿China, Romania, Russian¿Fed., South Africa, Spain, United Kingdom, Uruguay and Singapore.¿¿¿¿
Recall number
Z-0355-2023
Recall status
Open, Classified
CDRH record ID
196755
FDA classified
2022-12-02
Recall event number
91108

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗